상세 보기
DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): a subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features
- Holtick, U.;
- Mateos, M. Victoria;
- Robak, P.;
- Hus, M.;
- Fu, C.;
- 외 15명
Citations
WEB OF SCIENCE
0- 제목
- DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): a subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features
- 저자
- Holtick, U.; Mateos, M. Victoria; Robak, P.; Hus, M.; Fu, C.; Zherebtsova, V; Ward, C.; Ho, P.; Hajek, P.; Kim, K.; Dimopoulos, M.; Cerchione, C.; Pirooz, N.; Mckeown, A.; Lin, C. Paul; Baig, H.; Eccersley, L.; Roy-Ghanta, S.; Opalinska, J. B.; Hungria, V
- 발행일
- 2025-10-20
- 유형
- Meeting Abstract
- 권
- 48
- 호
- SUPPL 2